Platform science
Why half-life extension matters more than binding affinity alone
The engineering tradeoffs behind our antibody platform, and why we optimized for durability first.
Clinical-stage biotechnology
Antibody therapeutics designed for diseases with no good options left
Calyxis develops monoclonal antibody therapeutics for autoimmune and inflammatory disease, with three programs currently in clinical development.
Trusted by teams at
- Tidewater Bio Ventures
- Larkspur Clinical Research
- Westbury Rheumatology Institute
- Quintrell Biologics
- Fallowfield Patient Alliance
- Sorrel Cell Analytics
Our pipeline
Three programs, one shared mechanism of action
Each program targets a distinct autoimmune indication, but all three build on the same antibody engineering platform developed in our founding lab.
CLX-101: Rheumatoid arthritis
Phase 2 monoclonal antibody targeting a novel inflammatory pathway, currently enrolling across 40 sites.
CLX-204: Psoriatic disease
Phase 1b antibody therapeutic showing durable response in early-stage dose escalation cohorts.
CLX-309: Inflammatory bowel disease
Preclinical program advancing toward IND filing, building on validated mechanism from CLX-101.
Antibody engineering platform
Our proprietary platform for designing high-affinity antibodies with extended half-life profiles.
Translational research
In-house biomarker and translational science supporting patient stratification across all programs.
Manufacturing partnerships
Strategic CDMO partnerships supporting clinical and future commercial-scale antibody production.
Antibody research since 2016, now three clinical programs
- Patients dosed to date
- 640
- Patients dosed to date
- Peer-reviewed publications
- 28
- Peer-reviewed publications
- Research staff
- 95
- Research staff
- Capital raised
- $310M
- Capital raised
Program milestones
Recent progress across our pipeline
Clinical development is slow by nature. These are the milestones we can share publicly as programs advance.
Rheumatoid arthritis
CLX-101 Phase 2
Interim Phase 2 data showed durable response rates exceeding the standard-of-care comparator arm across the primary efficacy endpoint.
58%of patients reached primary endpoint at 24 weeks
Psoriatic disease
CLX-204 Phase 1b
Dose escalation completed with a clean safety profile, supporting advancement into expanded Phase 2 cohort design.
Zerodose-limiting toxicities observed across all cohorts
About Calyxis
Founded in a university lab studying antibody half-life
Calyxis was founded in 2016 out of research on antibody engineering conducted at MIT, focused on extending therapeutic half-life without sacrificing binding affinity. That founding research became the platform underlying all three of our current clinical programs.
- Mechanism before indication
- We pursue mechanisms we understand deeply, then find the indications where they matter most.
- Publish the negative results too
- Our research team publishes failed approaches alongside successes, which is rarer than it should be.
- Patient advocacy involvement
- Patient advocacy groups are involved in trial design decisions from Phase 1 onward.
- Platform, not a single asset
- We built a reusable antibody engineering platform rather than betting the company on one molecule.
Leadership
Dr. Meredith Ansah
Founder & CEO
Dr. Samuel Iverson
Chief Scientific Officer
Dr. Wen Zhao
Chief Medical Officer
Anna Kowalski
Chief Operating Officer
What our partners and investors say
“Calyxis publishes their negative data as rigorously as their wins. That's rare, and it's part of why we stayed invested across three rounds.”
Devika Rao
Partner, Tidewater Bio Ventures
“The CLX-101 Phase 2 interim data was some of the cleanest I've reviewed this cycle: real separation from standard of care, not a marginal signal.”
Dr. Frank Osterhout
Independent Clinical Advisor, Larkspur Clinical Research
“Their translational science team caught a patient stratification signal in Phase 1 that meaningfully improved the Phase 2 trial design.”
Dr. Louise Carrow
Principal Investigator, Westbury Rheumatology Institute
Science notes
From our research team
Clinical development
What we learned from a Phase 1b safety signal we didn't expect
A candid research note on an early finding that changed our Phase 2 dosing strategy for CLX-204.
Clinical operations
Designing trials with patient advocacy groups from day one
How earlier patient input changed our endpoint selection and improved enrollment velocity.
Frequently asked questions
CLX-101 for rheumatoid arthritis is in Phase 2 clinical development, currently enrolling across 40 sites.
Follow our pipeline as programs advance through the clinic
We publish program updates as milestones are reached, and investors and research partners can reach our team directly.